The objective of this study is to compare the long-term efficacy of pasireotide LAR vs. octreotide LAR in controlling diarrhea and flushing in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by the maximum approved doses of somatostatin analogues.
To participate in this study, patients must be at least 18 years of age or older and must:
Exclusion criteria for this study includes:
Other protocol-defined inclusion and exclusion criteria may apply.
For more information, contact the clinical research coordinator at 919-668-1861.